Oramed Pharmaceuticals Shares Are Trading Higher After the Company Announced a $20 Million Buyback Program and Finalized Its Joint Venture With Hefei Tianhui Biotech.
Oramed Pharmaceuticals Shares Are Trading Higher After the Company Announced a $20 Million Buyback Program and Finalized Its Joint Venture With Hefei Tianhui Biotech.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.